These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Low-dose "natural" alpha-interferon in B-cell derived chronic lymphocytic leukemia.
    Author: Pozzato G, Franzin F, Moretti M, Tulissi P, Pecorari P, Melato M, Zacchi T, Evangelisti P, Campanacci L.
    Journal: Haematologica; 1992; 77(5):413-7. PubMed ID: 1483591.
    Abstract:
    BACKGROUND: Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose "natural" IFN was evaluated in terms of efficacy and safety. METHODS: Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. RESULTS: Overall lymphocyte count decreased from 13,050 +/- 3,200 to 7,500 +/- 2,940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. CONCLUSION: Low dose "natural" alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.
    [Abstract] [Full Text] [Related] [New Search]